Equities research analysts expect that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) will post $0.96 earnings per share for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Valeant Pharmaceuticals Intl’s earnings, with estimates ranging from $0.72 to $1.29. Valeant Pharmaceuticals Intl posted earnings per share of $1.27 in the same quarter last year, which would suggest a negative year-over-year growth rate of 24.4%. The company is scheduled to announce its next quarterly earnings report before the market opens on Tuesday, May 9th.
On average, analysts expect that Valeant Pharmaceuticals Intl will report full year earnings of $3.88 per share for the current fiscal year, with EPS estimates ranging from $3.37 to $4.23. For the next year, analysts expect that the firm will post earnings of $4.39 per share, with EPS estimates ranging from $3.44 to $6.28. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Valeant Pharmaceuticals Intl.
Valeant Pharmaceuticals Intl (NYSE:VRX) last posted its quarterly earnings results on Tuesday, February 28th. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.20 by $0.06. The firm earned $2.40 billion during the quarter, compared to the consensus estimate of $2.34 billion. Valeant Pharmaceuticals Intl had a positive return on equity of 43.81% and a negative net margin of 22.17%. The business’s revenue was down 12.9% compared to the same quarter last year. During the same period last year, the company earned $1.55 earnings per share.
Several research firms have issued reports on VRX. Deutsche Bank AG set a $20.00 target price on Valeant Pharmaceuticals Intl and gave the stock a “hold” rating in a research report on Saturday, January 21st. Wells Fargo & Co set a $11.00 target price on Valeant Pharmaceuticals Intl and gave the stock a “sell” rating in a research report on Saturday, February 25th. Piper Jaffray Companies restated an “outperform” rating and set a $10.00 target price on shares of Valeant Pharmaceuticals Intl in a research report on Friday, April 14th. Royal Bank of Canada dropped their target price on Valeant Pharmaceuticals Intl from $29.00 to $22.00 and set a “sector perform” rating on the stock in a research report on Tuesday, February 14th. Finally, BTIG Research restated a “neutral” rating on shares of Valeant Pharmaceuticals Intl in a research report on Friday, March 3rd. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $24.32.
Valeant Pharmaceuticals Intl (NYSE:VRX) traded down 1.39% on Thursday, reaching $9.25. The company’s stock had a trading volume of 9,062,943 shares. The firm’s 50-day moving average price is $10.15 and its 200 day moving average price is $14.81. The company’s market cap is $3.22 billion. Valeant Pharmaceuticals Intl has a 52-week low of $8.31 and a 52-week high of $38.50.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/05/20/valeant-pharmaceuticals-intl-inc-vrx-expected-to-post-earnings-of-0-96-per-share-updated-updated.html.
In related news, insider Valueact Capital Master Fund, acquired 3,000,000 shares of Valeant Pharmaceuticals Intl stock in a transaction dated Tuesday, March 14th. The shares were purchased at an average cost of $10.82 per share, with a total value of $32,460,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Schutter Richard U. De acquired 10,000 shares of Valeant Pharmaceuticals Intl stock in a transaction dated Wednesday, March 15th. The shares were bought at an average cost of $10.80 per share, for a total transaction of $108,000.00. Following the completion of the purchase, the director now directly owns 25,190 shares of the company’s stock, valued at approximately $272,052. The disclosure for this purchase can be found here. Insiders have acquired 3,034,000 shares of company stock worth $32,825,280 in the last 90 days. Company insiders own 16.37% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Financial Architects Inc boosted its position in shares of Valeant Pharmaceuticals Intl by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares during the period. LeJeune Puetz Investment Counsel LLC bought a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $123,000. Cambridge Advisors Inc. boosted its position in shares of Valeant Pharmaceuticals Intl by 0.6% in the first quarter. Cambridge Advisors Inc. now owns 12,650 shares of the specialty pharmaceutical company’s stock worth $140,000 after buying an additional 75 shares during the period. US Bancorp DE boosted its position in shares of Valeant Pharmaceuticals Intl by 141.0% in the third quarter. US Bancorp DE now owns 5,745 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 3,361 shares during the period. Finally, Frontier Wealth Management LLC bought a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $149,000. 64.34% of the stock is currently owned by hedge funds and other institutional investors.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.